Fig. 2From: A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritisMean active joint counts, swollen joint counts, tender joint counts, and tender enthesis counts registered during the entire duration of the study (RCT + OLE phases) by treatment group according to randomization. A Mean active joint count (primary outcome). B–D Mean number of swollen joints, tender joints, and tender enthesis, respectively. All comparisons showed a significant difference between infliximab and placebo by week 12. In the open-label extension, in which all patients received infliximab, the mean of each outcome showed a sustained response to infliximabBack to article page